TNGX
Tango Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +10.0% ·
share flow +30.0% ·
net new positions +9.1%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 595.91K | $14.87M | n/a | n/a |
| Q2 2026 | 97 | +23 | 90.52M | $2.83B | +25 | −2 |
| Q1 2026 | 77 | 0 | 72.21M | $1.51B | +9 | −9 |
| Q4 2025 | 76 | 0 | 64.83M | $574.42M | +1 | −1 |
| Q3 2025 | 19 | +2 | 27.21M | $228.58M | +3 | −1 |
| Q2 2025 | 14 | 0 | 22.55M | $115.47M | +1 | −1 |
| Q1 2025 | 11 | +1 | 6.63M | $9.09M | +2 | −1 |
| Q4 2024 | 10 | 0 | 4.99M | $15.42M | +3 | −3 |
| Q3 2024 | 9 | -1 | 6.83M | $52.57M | +1 | −2 |
| Q2 2024 | 10 | n/a | 5.64M | $48.44M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Marshall Wace ✦ | 1.84M | New | $2.52M | 0.0% | New | 1 | SEC ↗ ×2 |
| 2 | Millennium Management ✦ | 1.47M | +489.2% | $2.02M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 1.38M | -0.2% | $1.90M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 4 | State Street Global Advisors ✦ (passive) | 1.14M | -7.0% | $1.57M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 5 | Fisher Asset Management ✦ | 224.08K | +44.6% | $306,985 | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | Renaissance Technologies ✦ | 174.50K | +711.6% | $239,065 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 7 | AQR Capital Management ✦ | 142.11K | New | $194,688 | 0.0% | New | 1 | SEC ↗ ×5 |
| 8 | Citadel Advisors ✦ | 106.50K | -93.5% | $145,908 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 9 | D. E. Shaw & Co. ✦ | 68.27K | -40.5% | $93,528 | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 10 | Two Sigma Investments ✦ | 52.90K | +17.6% | $72,476 | 0.0% | ▲ Add | 4 | SEC ↗ |
| 11 | T. Rowe Price ✦ | 22.25K | +6.0% | $31,000 | 0.0% | ▲ Add | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Marshall Wace | $2.52M | 0.0% |
| AQR Capital Management | $194,688 | 0.0% |
Exited
| Wellington Management | $427,183 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 193 holders, 180.17M shares, $3.72B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 600 sh · $15,192
Officer · 26.40K sh · $645,604
Officer · 2.40K sh · $60,412
Officer · 700 sh · $15,962
Officer · 5.10K sh · $122,238
Officer · 27.00K sh · $603,909
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology